对审查的反复事件的分析进行分布式归算
1Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA.
Statistics in medicine
|April 29, 2024
概括
对临床试验中复发事件数据的敏感性分析至关重要. 分布归算 (DI) 与缺少数据的多重归算 (MI) 相比,提供了更好的标准误差估计,提高了试验结论的稳定性.
科学领域:
- 生物统计学 生物统计学
- 临床试验 临床试验
- 流行病学 流行病学
背景情况:
- 具有反复事件终点的长度临床试验经常遇到缺失的数据.
- 主要分析通常假设数据是随机缺失的,因此需要对强度进行敏感性分析.
- 基于对照的归算方法对于优越性试验中的保守假设是有价值的.
研究的目的:
- 为基于对照的反复事件敏感性分析提出分布式归算 (DI) 与野生启动差异估计.
- 在处理缺失的反复事件数据时,评估DI与多重归算 (MI) 的性能.
主要方法:
- 开发了一种分布式归算 (DI) 方法,用于反复事件数据.
- 整合了DI的野生启动变异估计程序.
- 在I型糖尿病临床试验中应用DI,并进行模拟研究.
主要成果:
- 分布归算 (DI) 提供了比多重归算 (MI) 用鲁宾的结合规则更合理的标准误差估计.
- 在基于对照的反复事件敏感性分析中,DI表现得更好.
- 拟议的方法已成功应用于I型糖尿病试验.
结论:
- 分布归算 (DI) 是一种推的方法,用于基于对照的灵敏度分析,用于具有重复事件的纵向试验.
- 在处理缺失的反复事件数据时,DI提高了统计推断的可靠性.
- 这些发现支持使用DI进行对临床试验数据的可靠分析.
相关概念视频
Censoring Survival Data
87
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
87
Assumptions of Survival Analysis
125
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
125
Comparing the Survival Analysis of Two or More Groups
178
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
178
Introduction To Survival Analysis
221
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
221
Truncation in Survival Analysis
203
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
203
Kaplan-Meier Approach
133
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
133


